Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 150Stomach Neoplasms 52Neoplasms 49Pancreatic Neoplasms 41Neoplasm Metastasis 32Squamous Cell Carcinoma of Head and Neck 26Head and Neck Neoplasms 25Esophageal Neoplasms 24Colonic Neoplasms 22Rectal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 19Esophageal Squamous Cell Carcinoma 15Adenocarcinoma 14Adenocarcinoma Of Esophagus 12Cholangiocarcinoma 11Biliary Tract Neoplasms 11Ovarian Neoplasms 9Triple Negative Breast Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma 7Urinary Bladder Neoplasms 6Sarcoma 6Keratosis, Actinic 6Gastrointestinal Neoplasms 6Endometrial Neoplasms 6Carcinoma, Squamous Cell 6Advanced Solid Tumors 6

Interventions

Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cirrhosis, Familial, with Pulmonary Hypertension × Fluorouracil × Clear all
NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

TransThera Sciences (Nanjing), Inc.

Phase 3 Not yet recruiting
138 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡